证券代码：002873 证券简称：新天药业 公告编号：2025-054 贵阳新天药业股份有限公司 关于对参股公司增资并受让其部分股权暨关联交易 的进展公告 一、对参股公司增资并受让其部分股权暨关联交易概述 贵阳新天药业股份有限公司（以下简称"公司"）于2025年8月21日召开了第 八届董事会第二次会议，审议通过了《关于对参股公司增资并受让其部分股权暨 关联交易的议案》，同意公司使用自有资金4,000万元以"增资+受让"方式，增 加对参股公司上海汇伦医药股份有限公司（以下简称"汇伦医药"）的股权投资， 其中：以2,000万元对汇伦医药进行增资，增资对应可获得汇伦医药股份235.2941 万股；以2,000万元受让湖北苹湖创业投资有限公司（以下简称"苹湖创投"） 持有的汇伦医药股份235.2941万股（以下将增资事项及受让汇伦医药部分股权合 称为"本次交易"）。同时参与汇伦医药本次增资的还有新增股东烟台天自汇莱 创业投资基金合伙企业（有限合伙）增资3,700万元，新增股东北京金慧丰投资 管理有限公司增资1,500万元，各主体本次增资合计7,200万元，增资价格均为人 民币8.5元/股。参与汇伦医药本次增资的各投资 ...

Company Overview - Xintian Pharmaceutical Co., Ltd. is located in Guizhou Province, established on August 11, 1995, and listed on May 19, 2017. The company specializes in the research, production, and sales of traditional Chinese medicine [1] - The main business revenue composition includes gynecological products (74.16%), urological products (17.04%), heat-clearing and detoxifying products (7.79%), and others (1.01%) [1] Stock Performance - As of September 17, the stock price of Xintian Pharmaceutical decreased by 2.06%, trading at 11.41 CNY per share, with a total market capitalization of 2.785 billion CNY [1] - Year-to-date, the stock price has increased by 21.72%, but it has seen a decline of 0.35% over the last five trading days and a 16.53% drop over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on August 20, where it recorded a net purchase of 56.32 million CNY [1] Financial Performance - For the first half of 2025, Xintian Pharmaceutical reported a revenue of 358 million CNY, a year-on-year decrease of 18.88%, and a net profit attributable to shareholders of 5.77 million CNY, down 80.99% year-on-year [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 61.87 million CNY distributed over the past three years [3] Shareholder Information - As of September 10, the number of shareholders decreased to 33,700, a reduction of 5.83%, while the average circulating shares per person increased by 6.19% to 7,083 shares [2] - As of June 30, 2025, the top ten circulating shareholders included a new entry, Nuoan Multi-Strategy Mixed A, holding 1.0731 million shares, while Baodao Yuanhang Mixed A exited the top ten list [3]

Group 1 - The company, New Tian Pharmaceutical, reported that as of September 10, 2025, the number of shareholders is 33,696 [2]

Group 1 - Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The company's business scope includes elderly care services, remote health management services, medical research and experimental development, as well as engineering and technology research and experimental development [1] - The company is wholly owned by Xintian Pharmaceutical (002873) [1]

Group 1 - The company, New Tian Pharmaceutical, reported that as of August 29, 2025, the number of shareholders is 35,781 [2]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its health food production and sales capabilities [2] Company Overview - Guizhou Xintian Pharmaceutical was founded on August 11, 1995, with a registered capital of 2,441.03806 million RMB [2] - The company specializes in the research, production, and sales of traditional Chinese medicine [2] - The current chairman is Dong Dalun, and the company employs 1,682 people [2] Business Strategy - The new subsidiary will focus on health food production, food sales, and health consulting services [2] - The investment aligns with the company's strategic development plan and aims to diversify its product matrix and improve operational scale and profitability [2] Financial Performance - Projected revenues for 2024 and Q2 2025 are 858 million RMB, 193 million RMB, and 358 million RMB, with year-on-year changes of -10.11%, 8.93%, and -18.88% respectively [3] - The net profit attributable to the parent company for the same periods is projected to be 52.3229 million RMB, 4.1875 million RMB, and 5.7661 million RMB, with year-on-year declines of -35.30%, -73.11%, and -80.99% respectively [3] - The company's asset-liability ratios for the same periods are 38.75%, 37.48%, and 37.03% [3] Risk Factors - The company has 31 internal risk alerts and 38,039 external risk alerts, indicating a significant level of risk exposure [3]

Group 1 - The company announced that its wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction [1] - The acquisition of this patent is expected to enhance the company's intellectual property protection system and strengthen its core competitiveness through continuous innovation [1] - The company specializes in the research, development, production, and sales of traditional Chinese medicine, focusing on gynecological and urological medications, among other areas [1][2] Group 2 - The company adheres to a philosophy of combining traditional formulas with modern technology to improve clinical efficacy, ensuring a comprehensive approach to drug development [2] - The company’s product lineup includes unique varieties that cover multiple therapeutic areas, with a strong emphasis on clinical efficacy and inclusion in national basic drug and medical insurance directories [3] - The leading products, such as Kuntai capsules and Ningpitai capsules, are recognized as unique patented varieties with significant market barriers and pricing advantages [3] Group 3 - In the first half of 2025, the company achieved a revenue of 358 million yuan and a net profit of 5.77 million yuan attributable to shareholders [4]

Core Points - The company, New Tian Pharmaceutical, announced that its wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., has received a patent certificate from the National Intellectual Property Administration for an invention titled "A Method for Detecting the Fingerprint Spectrum of Ginkgo Biloba Decoction and Its Fingerprint Spectrum" [2] Summary by Category - **Company Announcement** - New Tian Pharmaceutical has successfully obtained a patent for a new method related to Ginkgo Biloba [2] - **Intellectual Property** - The patent is aimed at enhancing the detection and analysis of Ginkgo Biloba decoction, which may provide a competitive edge in the pharmaceutical industry [2]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The company has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its pharmaceutical industry layout and accelerate the research and development of health food [1][2] - The subsidiary is registered with a capital of 10 million RMB and will focus on various health food production and sales, including special medical purpose formula foods and infant formula foods [1][2] - This investment aligns with the company's strategic development plan to improve its diversified product matrix and aims to enhance overall profitability and risk resistance [1][2] Group 2 - The establishment of the subsidiary is not expected to harm the interests of the company or its shareholders and will not negatively impact the company's operations [2] - The company plans to conduct its business activities prudently and in compliance with regulations, aiming for favorable investment returns while being aware of potential market and policy risks [2]